OPTN News and Press, OptiNose Inc. From 06/22/20

YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upda...

YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “B...

YARDLEY, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeti...

YARDLEY, Penn., May 26, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upd...

YARDLEY, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business updat...

OptiNose, Inc. (OPTN) Q1 2020 Earnings Conference Call May 7, 2020 16:15 ET Company Participants Jonathan Neely - Vice President of Investor Relations Peter Miller - Chief Executive Officer Keith Goldan - Chief Financial Officer Vic Clavelli - Chief Commercial Officer Confer...

Image source: The Motley Fool. OptiNose, Inc.   (NASDAQ: OPTN) Q1 2020 Earnings Call May 7, 2020 , 4:15 p.m. ET Operator Continue reading

The following slide deck was published by OptiNose, Inc. in conjunction with their 2020 Q1 earnings Read more ...

OptiNose (NASDAQ: OPTN ): Q1 GAAP EPS of -$0.63 beats by $0.03 . More news on: OptiNose, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company reports first quarter 2020 XHANCE net revenue of $7.1 million First quarter 2020 XHANCE prescriptions increased 149% from first quarter 2019 Conference call and webcast to be held today at 4:15 p.m. Eastern Time YARDLEY, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Optinose ...